drugset
drugset / Trial / NCT05535244

A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma

NCT05535244 ↗

Phase 1/2 Active not recruiting 90 enrolled Hoffmann-La Roche
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study will evaluate the efficacy, safety, and pharmacokinetics of cevostamab in participants with relapsed or refractory multiple myeloma (R/R MM) via intravenous (IV) infusion.

Timeline

Start
2022-10-17
Primary completion
2027-02-26
Completion
2027-02-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Cevostamab Monoclonal antibody — Intravenous
Background Tocilizumab Monoclonal antibody — —

Indications

plasma cell myeloma